A Phase 1 Open-Label Multicenter Study to Assess Safety Tolerability PK and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors

Brief description of study

You can participate in this study if you are diagnosed with any of the advanced solid tumors found in any of the organ systems. The purpose of this study is to assess the Safety, Tolerability, and Efficacy of the study drug (MK-1084) individually, and in Combination with the study drug (Pembrolizumab) in subjects with KRASG12C mutant advanced solid tumors. The study is also being done to learn more about how the study drugs are absorbed (taken up in the body), metabolized (broken down by the body), distributed (circulated in the body), and eliminated (passed out of the body). The patients will be monitored and taken care of while on these medications during the entire study period.

Clinical Study Identifier: s22-00270
ClinicalTrials.gov Identifier: NCT05067283

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.